27908689|t|PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
27908689|a|Statin treatment and variants in the gene encoding HMG-CoA reductase are associated with reductions in both the concentration of LDL cholesterol and the risk of coronary heart disease, but also with modest hyperglycaemia, increased bodyweight, and modestly increased risk of type 2 diabetes, which in no way offsets their substantial benefits. We sought to investigate the associations of LDL cholesterol -lowering PCSK9 variants with type 2 diabetes and related biomarkers to gauge the likely effects of PCSK9 inhibitors on diabetes risk. In this mendelian randomisation study, we used data from cohort studies, randomised controlled trials, case control studies, and genetic consortia to estimate associations of PCSK9 genetic variants with LDL cholesterol, fasting blood glucose, HbA1c, fasting insulin, bodyweight, waist-to-hip ratio, BMI, and risk of type 2 diabetes, using a standardised analysis plan, meta-analyses, and weighted gene-centric scores. Data were available for more than 550 000 individuals and 51 623 cases of type 2 diabetes. Combined analyses of four independent PCSK9 variants (rs11583680, rs11591147, rs2479409, and rs11206510) scaled to 1 mmol/L lower LDL cholesterol showed associations with increased fasting glucose (0·09 mmol/L, 95% CI 0·02 to 0·15), bodyweight (1·03 kg, 0·24 to 1·82), waist-to-hip ratio (0·006, 0·003 to 0·010), and an odds ratio for type diabetes of 1·29 (1·11 to 1·50). Based on the collected data, we did not identify associations with HbA1c (0·03%, -0·01 to 0·08), fasting insulin (0·00%, -0·06 to 0·07), and BMI (0·11 kg/m(2), -0·09 to 0·30). PCSK9 variants associated with lower LDL cholesterol were also associated with circulating higher fasting glucose concentration, bodyweight, and waist-to-hip ratio, and an increased risk of type 2 diabetes. In trials of PCSK9 inhibitor drugs, investigators should carefully assess these safety outcomes and quantify the risks and benefits of PCSK9 inhibitor treatment, as was previously done for statins. British Heart Foundation, and University College London Hospitals NHS Foundation Trust (UCLH) National Institute for Health Research (NIHR) Biomedical Research Centre.
27908689	0	5	PCSK9	T017	UMLS:C1426592
27908689	6	22	genetic variants	T017	UMLS:C0678941
27908689	35	50	type 2 diabetes	T038	UMLS:C0011860
27908689	54	83	mendelian randomisation study	T062	UMLS:C2718019
27908689	84	90	Statin	T103	UMLS:C0360714
27908689	91	100	treatment	T058	UMLS:C0087111
27908689	105	125	variants in the gene	T017	UMLS:C0678941
27908689	135	152	HMG-CoA reductase	T103	UMLS:C0020374
27908689	213	228	LDL cholesterol	T103	UMLS:C0023824
27908689	245	267	coronary heart disease	T038	UMLS:C0010068
27908689	290	304	hyperglycaemia	T038	UMLS:C0020456
27908689	306	326	increased bodyweight	T033	UMLS:C0043094
27908689	359	374	type 2 diabetes	T038	UMLS:C0011860
27908689	473	488	LDL cholesterol	T103	UMLS:C0023824
27908689	499	504	PCSK9	T017	UMLS:C1426592
27908689	505	513	variants	T017	UMLS:C0678941
27908689	519	534	type 2 diabetes	T038	UMLS:C0011860
27908689	547	557	biomarkers	T201	UMLS:C0005516
27908689	589	605	PCSK9 inhibitors	T103	UMLS:C4051515
27908689	632	661	mendelian randomisation study	T062	UMLS:C2718019
27908689	697	725	randomised controlled trials	T062	UMLS:C0206035
27908689	727	747	case control studies	T062	UMLS:C0007328
27908689	799	804	PCSK9	T017	UMLS:C1426592
27908689	805	821	genetic variants	T017	UMLS:C0678941
27908689	827	842	LDL cholesterol	T103	UMLS:C0023824
27908689	844	865	fasting blood glucose	T033	UMLS:C1261430
27908689	867	872	HbA1c	T103	UMLS:C0019018
27908689	874	881	fasting	T033	UMLS:C0015663
27908689	882	889	insulin	T103	UMLS:C0021641
27908689	923	926	BMI	T201	UMLS:C1305855
27908689	940	955	type 2 diabetes	T038	UMLS:C0011860
27908689	965	991	standardised analysis plan	T062	UMLS:C0936012
27908689	993	1006	meta-analyses	T062	UMLS:C0920317
27908689	1084	1095	individuals	T098	UMLS:C0237401
27908689	1116	1131	type 2 diabetes	T038	UMLS:C0011860
27908689	1133	1150	Combined analyses	T062	UMLS:C0936012
27908689	1171	1176	PCSK9	T017	UMLS:C1426592
27908689	1177	1185	variants	T017	UMLS:C0678941
27908689	1187	1197	rs11583680	T017	UMLS:C0678941
27908689	1199	1209	rs11591147	T017	UMLS:C0678941
27908689	1211	1220	rs2479409	T017	UMLS:C0678941
27908689	1226	1236	rs11206510	T017	UMLS:C0678941
27908689	1263	1278	LDL cholesterol	T103	UMLS:C0023824
27908689	1304	1329	increased fasting glucose	T033	UMLS:C0920108
27908689	1473	1481	diabetes	T038	UMLS:C0011847
27908689	1573	1578	HbA1c	T103	UMLS:C0019018
27908689	1603	1610	fasting	T033	UMLS:C0015663
27908689	1611	1618	insulin	T103	UMLS:C0021641
27908689	1647	1650	BMI	T201	UMLS:C1305855
27908689	1682	1687	PCSK9	T017	UMLS:C1426592
27908689	1688	1696	variants	T017	UMLS:C0678941
27908689	1719	1734	LDL cholesterol	T103	UMLS:C0023824
27908689	1773	1795	higher fasting glucose	T033	UMLS:C0920108
27908689	1872	1887	type 2 diabetes	T038	UMLS:C0011860
27908689	1892	1898	trials	T062	UMLS:C0008976
27908689	1902	1917	PCSK9 inhibitor	T103	UMLS:C4051515
27908689	1918	1923	drugs	T103	UMLS:C0013227
27908689	1925	1938	investigators	T097	UMLS:C0035173
27908689	2024	2039	PCSK9 inhibitor	T103	UMLS:C4051515
27908689	2040	2049	treatment	T058	UMLS:C0087111
27908689	2078	2085	statins	T103	UMLS:C0360714
27908689	2087	2111	British Heart Foundation	T092	UMLS:C0016617
27908689	2117	2173	University College London Hospitals NHS Foundation Trust	T092	UMLS:C0035172
27908689	2175	2179	UCLH	T092	UMLS:C0035172
27908689	2181	2253	National Institute for Health Research (NIHR) Biomedical Research Centre	T092	UMLS:C0035172